Physician profile
Richard White
NPI 1700840980
$1,448.12
in general payments reported to CMS, 2019-2025
31 companies · $52.57 in 2025
The $52.57 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $32.97 · 2021: $11.50 · 2022: $62.75 · 2023: $661 · 2024: $400 · 2025: $52.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.80 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.85 | 2022-2024 | Vraylar |
| Alkermes, INC. | $104.16 | 2019 | |
| Rigel Pharmaceuticals, INC. | $95.04 | 2023-2024 | Rezlidhia, Tavalisse |
| Pfizer INC. | $88.06 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.09 | 2023-2024 | Caplyta |
| Eisai INC. | $78.40 | 2023-2024 | |
| Puma Biotechnology, INC. | $76.57 | 2023-2024 | |
| Lilly USA, LLC | $76.20 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Pharmaceuticals, INC | $64.35 | 2019-2022 | |
| Daiichi Sankyo INC. | $55.83 | 2024-2025 | Enhertu, Datroway |
| Jazz Pharmaceuticals INC. | $50.40 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $44.38 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $42.32 | 2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $37.82 | 2023-2025 | |
| Beigene USA, INC. | $32.92 | 2020-2023 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $30.27 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $27.69 | 2023-2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $27.28 | 2023-2024 | |
| Gilead Sciences, INC. | $25.57 | 2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $18.54 | 2023 | Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2023 | Vpriv |
| Kite Pharma, INC. | $15.55 | 2023 | |
| Shire North American Group INC | $15.28 | 2019 | |
| Merck Sharp & Dohme LLC | $15.13 | 2023 | Keytruda |
| Amgen INC. | $15.02 | 2023 | Lumakras |
| Genmab U.S., INC. | $14.98 | 2024 | Epkinly |
| Coherus Oncology, INC. | $13.75 | 2020 | |
| Neurocrine Biosciences, INC. | $13.74 | 2019 | |
| Genentech USA, INC. | $13.38 | 2023 | Tecentriq |
| Celgene Corporation | $12.69 | 2023 | Reblozyl |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.